Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11519877 | 0.81 | PDK2 (0.32) | ALDH1A1TSHRKDM4E | |
| SCHEMBL11520353 | 0.81 | GAA (0.36) | HTTPOLBALDH1A1TSHRKDM4E | |
| SCHEMBL17986192 | 0.81 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL17986195 | 0.81 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL21526684 | 0.69 | ELANE (0.37) | — | |
| SCHEMBL11419786 | 0.68 | CYP3A4 (0.39) | KMT2ASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL6883947 | 0.67 | LMNA (0.41) | KMT2ASMN1; SMN2POLBALDH1A1TSHR | |
| SCHEMBL10448804 | 0.67 | GAA (0.35) | HTTKMT2APOLBALDH1A1TSHR | |
| SCHEMBL5696701 | 0.66 | HTT (0.42) | HTTKMT2ASMN1; SMN2POLBSIGMAR1 | |
| SCHEMBL9681362 | 0.66 | KMT2A (0.42) | HTTKMT2ASMN1; SMN2POLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222681-B1 | EFFICIENT ASPIRIN PRODRUGS | PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-02-17 | — | — | EP | disclosed |
| US-8486974-B2 | Efficient aspirin prodrugs | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2013-07-16 | — | — | US | disclosed |
| US-20110046182-A1 | EFFICIENT ASPIRIN PRODRUGS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2011-02-24 | — | — | US | disclosed |
| EP-2222681-A1 | EFFICIENT ASPIRIN PRODRUGS | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth (IE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080795-A1 | EFFICIENT ASPIRIN PRODRUGS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046182-A1 | EFFICIENT ASPIRIN PRODRUGS | COX15, PTGS1, CYP3A43 | HTT 4331/4885KMT2A 4796/4885SMN1; SMN2 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.